research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
Search
for
Sort by
Research
300-330 / 418 results
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Tofacitinib Citrate Alleviates Alopecia Universalis Symptoms in Recent Case Study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Gynostemma Pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth via the Wnt/Beta-Catenin Pathway
Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris
The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series
Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Novel TMEM173 Mutation and the Role of Disease-Modifying Alleles
A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Ruxolitinib for the Treatment of Severe Alopecia Areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research Spotlight in Plastic Surgery: October 2022
Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
research Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Good Efficacy Achieved by Baricitinib in the Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis with Alopecia Areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.